Form 4 for RMD ResMed|
Accepted 2022-11-23 00:00:00 ET · period of report 2022-11-23 · accession 0001127602-22-026363 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-23 | 2022-11-23 | RMD | Farrell Michael J. | CEO | A - Grant | $0.00 | +56.1K | 470.1K | +14% | $0 | |
| 2022-11-23 | 2022-11-23 | RMD | Farrell Michael J. | CEO | F - Tax | $224.40 | -33.2K | 436.9K | -7% | -$7.46M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | ResMed Common Stock | 2022-11-23 | A | A | 56,115 | $0.00 | 470,139 | D | — | — | |
| 2 | Common | ResMed Common Stock | 2022-11-23 | F | D | 33,239 | $224.40 | 436,900 | D | — | — |